Pressure BioSciences (PBIO) Stock Price, News & Analysis

Company Overview

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.

Key Stats

• Today's Range: $0.0045 to $0.0045
• 50-Day Range: $0.00 to $0.04
• 52-Week Range: $0.00 to $0.54
• Volume: 20,000 shs
• Average Volume: 56,061 shs
• Market Capitalization: $184,351.50
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PBIO Stock Analysis - Frequently Asked Questions

How have PBIO shares performed this year?

Pressure BioSciences' stock was trading at $0.33 at the beginning of the year. Since then, PBIO stock has decreased by 98.6% and is now trading at $0.0045.
View the best growth stocks for 2024 here.

How were Pressure BioSciences' earnings last quarter?

Pressure BioSciences, Inc. (OTCMKTS:PBIO) released its quarterly earnings data on Friday, September, 6th. The company reported ($0.22) earnings per share for the quarter. The company had revenue of $0.35 million for the quarter.

How do I buy shares of Pressure BioSciences?

Shares of PBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pressure BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pressure BioSciences investors own include Hydrofarm Holdings Group (HYFM), Advanced Micro Devices (AMD), Monaker Group (MKGI), Meta Materials (MMAT), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP) and Novavax (NVAX).

Company Calendar

• Last Earnings: 9/06/2024
• Today: 11/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: OTCMKTS:PBIO
• CUSIP: N/A
• CIK: 830656
• Web: www.pressurebiosciences.com
• Phone: 508-230-1828
• Fax: 508-230-1829
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,310,000.00
• Net Margins: -1,925.03%
• Pretax Margin: -1,924.97%
• Return on Equity: N/A
• Return on Assets: -1,078.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.02
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: $1.98 million
• Price / Sales: 0.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.29) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 40,967,000
• Free Float: 36,543,000
• Market Cap: $184,351.50
• Optionable: Not Optionable
• Beta: -0.14